OBJECTIVE: Left ventricular (LV) end-systolic volume indexed to body surface area (ESVI) is a simple yet powerful echocardiographic marker of LV remodeling that can be measured easily. The prognostic value of ESVI and its merit relative to other markers of LV remodeling in patients with coronary heart disease are unknown. METHODS: We examined the association of ESVI with hospitalization for heart failure (HF) and mortality in a prospective study of patients with coronary heart disease. RESULTS: Of the 989 participants, 110 (11%) were hospitalized for HF during 3.6 +/- 1.1 years of follow-up. Among participants in the highest ESVI quartile (> 25 mL/m(2)), 67 of 248 (27%) developed HF compared with 8 of 248 (3%) among those in the lowest quartile. The association between ESVI and HF hospitalization persisted after adjustment for potential confounders (hazard ratio 5.0, 95% confidence interval, 1.5-16.9; P = .01). CONCLUSION: ESVI > 25 mL/m(2) is an independent predictor of hospitalization for HF in patients with stable coronary heart disease.
OBJECTIVE: Left ventricular (LV) end-systolic volume indexed to body surface area (ESVI) is a simple yet powerful echocardiographic marker of LV remodeling that can be measured easily. The prognostic value of ESVI and its merit relative to other markers of LV remodeling in patients with coronary heart disease are unknown. METHODS: We examined the association of ESVI with hospitalization for heart failure (HF) and mortality in a prospective study of patients with coronary heart disease. RESULTS: Of the 989 participants, 110 (11%) were hospitalized for HF during 3.6 +/- 1.1 years of follow-up. Among participants in the highest ESVI quartile (> 25 mL/m(2)), 67 of 248 (27%) developed HF compared with 8 of 248 (3%) among those in the lowest quartile. The association between ESVI and HF hospitalization persisted after adjustment for potential confounders (hazard ratio 5.0, 95% confidence interval, 1.5-16.9; P = .01). CONCLUSION: ESVI > 25 mL/m(2) is an independent predictor of hospitalization for HF in patients with stable coronary heart disease.
Authors: A W Hamer; M Takayama; K A Abraham; A H Roche; A R Kerr; B F Williams; M C Ramage; H D White Journal: Circulation Date: 1994-12 Impact factor: 29.690
Authors: M St John Sutton; M A Pfeffer; T Plappert; J L Rouleau; L A Moyé; G R Dagenais; G A Lamas; M Klein; B Sussex; S Goldman Journal: Circulation Date: 1994-01 Impact factor: 29.690
Authors: Guanying Wang; Roy Y Kim; Isabella Imhof; Norman Honbo; Fu Sang Luk; Kang Li; Nikit Kumar; Bo-Qing Zhu; Delphine Eberlé; Daniel Ching; Joel S Karliner; Robert L Raffai Journal: J Cardiovasc Pharmacol Date: 2014-02 Impact factor: 3.105
Authors: Nadia El Harane; Anaïs Kervadec; Valérie Bellamy; Laetitia Pidial; Hany J Neametalla; Marie-Cécile Perier; Bruna Lima Correa; Léa Thiébault; Nicolas Cagnard; Angéline Duché; Camille Brunaud; Mathilde Lemitre; Jeanne Gauthier; Alexandra T Bourdillon; Marc P Renault; Yeranuhi Hovhannisyan; Solenne Paiva; Alexandre R Colas; Onnik Agbulut; Albert Hagège; Jean-Sébastien Silvestre; Philippe Menasché; Nisa K E Renault Journal: Eur Heart J Date: 2018-05-21 Impact factor: 29.983
Authors: Bryan Ristow; Sadia Ali; Beeya Na; Mintu P Turakhia; Mary A Whooley; Nelson B Schiller Journal: J Am Soc Echocardiogr Date: 2010-03-03 Impact factor: 5.251
Authors: Nisha Bansal; Jason Roy; Hsiang-Yu Chen; Rajat Deo; Mirela Dobre; Michael J Fischer; Elyse Foster; Alan S Go; Jiang He; Martin G Keane; John W Kusek; Emile Mohler; Sankar D Navaneethan; Mahboob Rahman; Chi-Yuan Hsu Journal: Am J Kidney Dis Date: 2018-05-18 Impact factor: 8.860
Authors: Sonya B Seif-Naraghi; Jennifer M Singelyn; Michael A Salvatore; Kent G Osborn; Jean J Wang; Unatti Sampat; Oi Ling Kwan; G Monet Strachan; Jonathan Wong; Pamela J Schup-Magoffin; Rebecca L Braden; Kendra Bartels; Jessica A DeQuach; Mark Preul; Adam M Kinsey; Anthony N DeMaria; Nabil Dib; Karen L Christman Journal: Sci Transl Med Date: 2013-02-20 Impact factor: 17.956